Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients

Mads Emil  Bjørn; Morten Orebo Holmström; Hans Carl Hasselbalch

doi:10.3109/10428194.2015.1046867

Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients

Mads Emil Bjørn, Morten Orebo Holmström, Hans Carl Hasselbalch

Department for Rheumatology and Spine Diseases

16 Citations (Scopus)

Abstract

We report 12 Danish myelofibrosis patients who have been treated successfully with ruxolitinib despite having low platelet counts (< 50 × 10(9)/L) during their treatment-course. The majority of the patients experienced marked clinical improvement. Serious side effects were only recorded in a single patient. It is concluded that JAK-inhibition with ruxolitinib is manageable in patients with low platelet counts and should be considered in symptomatic patients who otherwise might not be candidates for treatment.

Original language	English
Journal	Leukemia and Lymphoma
Volume	57
Issue number	1
Pages (from-to)	125-8
Number of pages	4
ISSN	1042-8194
DOIs	https://doi.org/10.3109/10428194.2015.1046867
Publication status	Published - 2016

Keywords

Aged
Aged, 80 and over
Blood Platelets
Denmark
Disease Management
Female
Humans
Janus Kinases
Male
Middle Aged
Mutation
Platelet Count
Primary Myelofibrosis
Protein Kinase Inhibitors
Pyrazoles
Severity of Illness Index
Thrombocytopenia
Treatment Outcome
Case Reports
Journal Article

Access to Document

10.3109/10428194.2015.1046867

Cite this

@article{e9339f85828c4b04a6c79c1ad094ab31,

title = "Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients",

abstract = "We report 12 Danish myelofibrosis patients who have been treated successfully with ruxolitinib despite having low platelet counts (< 50 × 10(9)/L) during their treatment-course. The majority of the patients experienced marked clinical improvement. Serious side effects were only recorded in a single patient. It is concluded that JAK-inhibition with ruxolitinib is manageable in patients with low platelet counts and should be considered in symptomatic patients who otherwise might not be candidates for treatment.",

keywords = "Aged, Aged, 80 and over, Blood Platelets, Denmark, Disease Management, Female, Humans, Janus Kinases, Male, Middle Aged, Mutation, Platelet Count, Primary Myelofibrosis, Protein Kinase Inhibitors, Pyrazoles, Severity of Illness Index, Thrombocytopenia, Treatment Outcome, Case Reports, Journal Article",

author = "Bj{\o}rn, {Mads Emil} and Holmstr{\"o}m, {Morten Orebo} and Hasselbalch, {Hans Carl}",

year = "2016",

doi = "10.3109/10428194.2015.1046867",

language = "English",

volume = "57",

pages = "125--8",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia

T2 - a report on 12 Danish patients

AU - Bjørn, Mads Emil

AU - Holmström, Morten Orebo

AU - Hasselbalch, Hans Carl

PY - 2016

Y1 - 2016

N2 - We report 12 Danish myelofibrosis patients who have been treated successfully with ruxolitinib despite having low platelet counts (< 50 × 10(9)/L) during their treatment-course. The majority of the patients experienced marked clinical improvement. Serious side effects were only recorded in a single patient. It is concluded that JAK-inhibition with ruxolitinib is manageable in patients with low platelet counts and should be considered in symptomatic patients who otherwise might not be candidates for treatment.

AB - We report 12 Danish myelofibrosis patients who have been treated successfully with ruxolitinib despite having low platelet counts (< 50 × 10(9)/L) during their treatment-course. The majority of the patients experienced marked clinical improvement. Serious side effects were only recorded in a single patient. It is concluded that JAK-inhibition with ruxolitinib is manageable in patients with low platelet counts and should be considered in symptomatic patients who otherwise might not be candidates for treatment.

KW - Aged

KW - Aged, 80 and over

KW - Blood Platelets

KW - Denmark

KW - Disease Management

KW - Female

KW - Humans

KW - Janus Kinases

KW - Male

KW - Middle Aged

KW - Mutation

KW - Platelet Count

KW - Primary Myelofibrosis

KW - Protein Kinase Inhibitors

KW - Pyrazoles

KW - Severity of Illness Index

KW - Thrombocytopenia

KW - Treatment Outcome

KW - Case Reports

KW - Journal Article

U2 - 10.3109/10428194.2015.1046867

DO - 10.3109/10428194.2015.1046867

M3 - Journal article

C2 - 25936872

SN - 1042-8194

VL - 57

SP - 125

EP - 128

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 1

ER -

Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this